ITGR · CIK 1114483
What Integer Holdings Corporation told the SEC could break it.
Integer Holdings' disclosures center on the materials and geography behind its medical-device manufacturing. Its implantable and device products rely on specialty and precious metals — platinum, iridium, tantalum, ruthenium, nickel cobalt, and others — whose price and supply swing with geopolitical conflict, government controls, and tariffs, with increases that can't always be passed to OEM customers squeezing margins. Much of its production is offshore (Mexico, Ireland, China, and elsewhere), exposing imports into the U.S. to tariffs on steel, copper, and goods from those countries, and for some critical raw materials it depends on a single supplier — materials whose lengthy internal and customer qualification makes replacements impossible to establish quickly.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Commodity & input dependence
- Specialty/precious metals — platinum, iridium, tantalum, ruthenium, nickel-cobalt, vanadium oxide, etc.medium
Integer's implantable and medical-device manufacturing relies on specialty and precious metals — including platinum, iridium, tantalum, nickel cobalt, ruthenium, vanadium oxide and carbon monofluoride, plus plastics — whose supply and price are susceptible to fluctuations from transportation issues, government price controls, industry bans, geopolitical conflicts (Ukraine, Middle East, China-Taiwan tensions) and tariffs. Rising global demand has pushed certain material prices higher, and increases that cannot be recovered through product pricing pressure margins. The company uses tactics such as bulk purchases, precious-metal forward buys, blanket orders and long-term contracts to secure supply, underscoring its exposure to these commodity markets.
“iridium, tantalum, nickel cobalt, ruthenium, vanadium oxide, carbon monoflouride and plastics, among others.”
SEC filing →As of 2026
Regulatory & policy
- Tariffs on steel/copper and imports into the U.S. from Mexico, Ireland, China and Canada — Integer's key offshore manufacturing locationsmedium
Integer manufactures a large share of its products outside the U.S. — including in Mexico (3 facilities), Ireland (3), Malaysia, China, the Dominican Republic, Uruguay, Costa Rica and Switzerland — and imports both finished products and raw materials into the U.S. (about 47% of sales are to customers outside the U.S.; ~53% of products ship to U.S. locations). It is therefore exposed to U.S. tariffs on steel and copper and to other tariffs imposed or threatened on imports into the U.S. from Canada, Mexico, Ireland and China. Quotas, duties, tariffs and import restrictions could raise the cost of products it manufactures abroad and pressure its profits and margins, especially where pass-through to OEM customers is limited.
“including the tariffs on steel and copper that the U.S. has imposed and other tariffs that the current U.S. presidential administration has imposed or threatened to impose, particularly relating to imports into the U.S. from Canada, Mexico and Ireland, and China.”
Sole-source dependency
- Single-source critical raw materials with lengthy internal + customer qualification — alternatives cannot be established quicklymedium
Integer depends on a continuous supply of raw materials from a limited number of suppliers, and for reasons of quality, cost-effectiveness or availability it obtains some raw materials from a single supplier. Because of the technically challenging specifications and the lengthy process required to qualify these materials both internally and with its medical-device OEM customers, it cannot quickly establish additional or replacement suppliers. An unforeseen interruption or delay in deliveries of single-source critical materials could leave Integer unable to obtain substitutes on a timely basis or at all, harming its ability to manufacture products profitably or on time — a significant risk given that regulated medical-device materials require re-qualification.
“For reasons of quality, cost effectiveness or availability, we obtain some raw materials from a single supplier.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”
Cited →“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”
Cited →“During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch